Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1423758-00-2
Molecular formula
C18H23FN4O8
Molecular weight
442.4 g/mol
Drug class
Diagnostic radiopharmaceuticalPSMA-targeted fluorine-18 PET imaging agent
Mechanism of action
A urea-based ligand binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. The fluorine-18 positron-emitting radionuclide enables PET visualisation of PSMA-expressing lesions.
Indications / reported uses
PET imaging of PSMA-positive lesions in men with prostate cancer when metastatic disease is suspected in candidates for initial definitive therapy or recurrence is suspected due to elevated PSA.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Piflufolastat Environmental Risk Assessment (ERA) (the Piflufolastat ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.